Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
Fabrice Cognasse, Director of Research – Scientific Director at The EFS in Auvergne-Rhône-Alpes and INSERM, shared on LinkedIn:
”New Publication – When Platelets Meet Artificial Intelligence!
I’m pleased to announce the publication of our latest article:
“Computational modeling of platelet activation signatures in response to diverse immune and hemostatic agonists”, now available in Platelets Journal (DOI: 10.1080/09537104.2025.2572982).
This study, a collaboration between SAnté INgéniérie BIOlogie St-Etienne (SAINBIOSE) (INSERM U1059 – Université Jean Monnet Saint-Etienne / École des Mines de Saint-Étienne), EFS Auvergne-Rhône-Alpes, and AltraBio (Lyon), introduces a computational model of platelet activation signatures using machine learning to identify stimulus-specific pathways triggered by immune and hemostatic agonists.
The work is supported by a recently filed patent (WO2021224236A1), combining experimental biology, mathematical modeling, and artificial intelligence to decipher the remarkable plasticity of platelets in thromboinflammatory contexts.
Congratulations to all my amazing co-authors —
Kim-Anh Nguyen-Peyre, Marco Heestermans, Charles Antoine Arthaud, Marie-Ange Eyraud, Amélie Prier, Simon de Bernard, Julien Nourikyan, Anne-Claire Duchez, Stéphane Avril, Olivier Garraud, Hind Hamzeh-Cognasse — for their dedication, teamwork, and scientific insight.
Special thanks to our funding partners: ANR, the French National Research Agency 22-CE17-0063 HEASY-PLAT), EFS, and the Les Amis de Rémi Association, for their continuous support.
This study exemplifies how computational modeling and data-driven biology can advance our understanding of platelet heterogeneity and open new perspectives for diagnosis and therapy in inflammation and thrombosis.”
Read the full article here.
Article: Computational modeling of platelet activation signatures in response to diverse immune and hemostatic agonists
Authors: Fabrice Cognasse, Kim Anh Nguyen, Marco Heestermans, Charles-Antoine Arthaud, Marie-Ange Eyraud, Amelie Prier, Simon de Bernard, Julien Nourikyan, Anne-Claire Duchez, Stephane Avril, Olivier Garraud, Hind Hamzeh-Cognasse
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh Reflects on International Plasma Awareness Week
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation